Frontier entered into a licence agreement with AFFiRiS and obtained exclusive rights to develop, manufacture and commercialize AFFITOPE^® AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan.

AFFITOPE^® AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large Phase I clinical study, demonstrated that it could lead to a substantial reduction in low-density lipoprotein cholesterol (LDLc); it is well-tolerated safe and elicited a humoral immune response against the PCSK9 target epitope.